alexa High Fluence Low Intensity Laser Irradiation Bioinhibits Viability and Proliferation of Lung Cancer Stem Cells | OMICS International
ISSN: 2157-7633
Journal of Stem Cell Research & Therapy
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

High Fluence Low Intensity Laser Irradiation Bioinhibits Viability and Proliferation of Lung Cancer Stem Cells

Anine Crous and Heidi Abrahamse*

Laser Research Centre, Faculty of Health Sciences, University of Johannesburg, South Africa

*Corresponding Author:
Heidi Abrahamse
Director, Laser Research Centre, Faculty of Health Sciences
University of Johannesburg, PO Box 17011, Johannesburg 2028
South Africa
Tel: +27 115596550
Fax: +27115596884
Email: [email protected]

Received date: November 29, 2016; Accepted date: December 12, 2016; Published date: December 19, 2016

Citation: Crous A, Abrahamse H (2016) High Fluence Low Intensity Laser Irradiation Bioinhibits Viability and Proliferation of Lung Cancer Stem Cells. J Stem Cell Res Ther 6:368. doi: 10.4172/2157-7633.1000368

Copyright: © 2016 Crous A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Stem Cell Research & Therapy


Small populations of pancreatic cancer cells from Patient Derived Xenografts (PDXs) were demonstrated to be highly tumorigenic and chemotherapy resistant. The cancer cells isolated from the xenograft tumor tissue were sorted by the previously reported "Cancer Stem Cell" (CSC) markers and tested their tumorigenic activity in the limiting dilution assay by inoculating into the immuno-deficient NOD/scid mice subcutaneously. The varied correlation between the CSC marker expression and the tumorigenic activity in the NOD/scid mice among the different PDXs indicates that the CSC markers of the individual pancreatic tumor patients could be different each other. Only a part of PDX tumor samples among the six examined could show a tight correlation between the tumor initiating activity and the selectively higher expression of cell surface markers CD24, CD44 and CD133. We also demonstrated that CD133/CD44 double positive population from the one PDX shows superior tumorigenic activity and gemcitabine treatment resistance. To illuminate the characteristically expressed genes which allow them to have tumorigenic activity and chemotherapy resistance, the CD133/CD44 double positive CSC faction was subjected to the gene expression analysis. Prominently higher expression of epiregulin (11.1-fold increase compared to the double negative population), interleukin-8 and CXCL5 (8.5- and 8.0-fold increases, respectively) were observed in the CSC fraction. These gene signatures of CSC suggest several key molecular mechanisms playing important roles in CSC biology and having possibilities as drug targets for CSC therapy.


Cancer stem cells; Low intensity laser irradiation; Proliferation; Cytotoxicity


CSCs: Cancer Stem Cells; LILI: Low Intensity Laser Irradiation; SC: Stem Cell; HH: Hedgehog; LF: Low Fluences; HF-LILI: High Fluence LILI; ROS: Reactive Oxygen Species


Cancer is the pathological disease state of a cell caused by genetic mutations allowing for characteristics such as irrepressible cell proliferation along with self-renewal, self-sustainability and evasion of normal cell cycle processes like cell death leading to tumour formation [1,2]. Lung cancer has been ascribed the title for leading cancer mortality rates globally [3]. Research attributed to lung cancer has been going on for the past decade in order to better understand its mechanism and to advance treatment and diagnosis [4]. Despite these advancements it still has an aggressive approach to treatments characterised by drug-resistance and the capability to metastasise [5]. Thus, remaining a primary threat contributing to the growing number of cancer mortality rates and relapse.

Metastasis, one of the contributing factors to poor prognosis of lung cancer has been ascribed to a specialised subset of cells possessing cancer properties [6]. The hypothesis supporting the above mentioned statement is the Cancer Stem Cell (CSC) hypothesis which describes cancer initiation and maintenance. The hypothesis states that an intermittent population of cancerous cells, having stem cell (SC) like characteristics, is responsible for tumour growth, resistance, and recurrence [7]. The term tumour-initiating cells are sometimes preferred, also referring to CSCs due to their tumour initiating capabilities and asymmetric cell division. The characteristics these cells portray are similar to those of SCs because of their ability to selfrenew, differentiate into specialised cells and most importantly migrate [8,9]. Along with normal SC characteristics the tumorigenic properties the cells display include multidrug resistance, the expression of antiapoptotic proteins, drug efflux pumps and tumour regeneration after treatment [10]. In SCs there are molecular pathways that maintain ‘stemness’ that are also found to be active in different cancers [2]. Proposing that mutations of these molecular pathways can cause abnormal cell growth. SCs quiescently reside in a SC-niche maintaining the cells. In CSCs this niche called the CSCs niche may promote enhanced DNA repair. The quiescent phenotype, as well as the high rate of DNA repair may contribute to their therapeutic resistance [11]. Research has proven the existence of these cells and have been found in various cancers [12]. Lung cancer patients have been shown to present with early disseminated disease irrespective of the size of the tumour. This would suggest that these tumours are enriched for CSCs [13]. Normal pulmonary precursor behaviour is guided by the Notch, Hedgehog (HH), and Wnt pathways also defining normal SCs. Irregular pathway signalling can lead to undesired expansion of pulmonary SCs which can develop into CSC lineages ultimately leading to lung cancer and tumour formation [14]. In addition to the genes involved in the Notch, Wnt, and HH pathways, there are numerous genetic markers associated with CSCs. CSCs have been identified and were isolated from different cancers including lung cancer. This was achieved by using antigenic markers displayed by normal SCs indicating their stem-ness [15]. A popular lung CSC marker which has been used to isolate the subpopulation of cells is CD133. The cells displayed properties that included the increased capability to self-renew, drug resistance and high tumorigenic potential as well as increased expression of stem-ness [16-18]. CD133, also known as Prominin-1, is a member of the pentaspan transmembrane (5-TM) glycoprotein family. In humans, the Prominin-1 gene is located on chromosome 4 p15 and encodes a 120-kD transmembrane glycoprotein [19], which localizes to membrane protrusions.

Photobiomodulation operates by way of photochemistry relying on specific factors such as wavelength, fluence, power density, pulse structure and treatment time when applied in biological tissue. Specific light-absorbing molecules can then be targeted. The light energy absorbed produces singlet oxygen or superoxide via singlet state excitation of oxygen molecules or electron reduction respectively. Similar to normal cells cancer cells also comprise of intracellular chromophores. Different cellular chromophores are stimulated at different wavelengths [20]. The photobiomodulative therapy Low Intensity Laser Irradiation (LILI) uses coherent light at a specific wavelength in the visible spectrum that consists of red and nearinfrared light between 600-1070 nm. Research shows that tissue penetration is optimal at these wavelengths. Cells or tissues that are exposed to visible red light and near-IR light have shown to either have a biostimulatory or bioinhibitory outcome [21]. The photobiological effect takes place at the mitochondrial level whereby chromophores are stimulated. Wavelength and fluence have various metabolic outcomes [22]. Biostimulatory responses showing an increase in viability and proliferation were seen in various cell lines when using LILI with wavelengths between 625-675 nm and Low Fluences (LF) ranging from 1 J/cm2 to 15 J/cm2 [23-27], however bioinhibition was achieved at longer wavelengths of 800-830 nm and fluence of ≥ 10 J/cm2 [24,28,29]. Studies have also shown that laser light have been able to cause cancer cell destruction by using high fluence LILI (HF-LILI) [30]. It has been reported by Wang et al. [31], that HF-LILI can induce apoptosis in lung cancer cells. The reason for apoptosis has been said to be due to an increase in reactive oxygen species (ROS) which is toxic to the cell, as a result of the endogenous photo acceptors in the cell being stimulated by LILI [32]. The reason behind implementation of LILI is due to evidence signifying that laser photons induce photo-bio modulation stimulating a significant amount of cellular biological effects having results where a stimudli was produced that increases cellular viability and proliferation. As well as stimuli causing a regressive response of bio modulation where there is a generation of reactive oxygen species (ROS) which are toxic to cancer cells and evidently leading to cellular death [20].

This exploratory study was aimed at investigating the possible outcomes that various laser intensities and wavelengths would have on isolated lung CSCs. Isolated lung CSCs, positive for the antigenic marker CD133, were irradiated with LF-LILI of 5-20 J/cm2 and a HF-LILI of 40 J/cm2. The lasers used emitted wavelengths of 636, 825 and 1060 nm. After treatment with low and high fluence LILI biochemical assays were conducted on the treated lung CSCs and their control groups over a time period of 24, 48 and 72 h to determine various cellular responses. Cellular viability, proliferation, and cytotoxicity assays allowed for various LILI treatment outcomes to be evaluated.

Materials and Methods

A group of CSCs, isolated from the lung cancer cell line A549, positive for the antigenic marker CD133 received treatment using LFLILI with fluences of 5-20 J/cm2 and HF-LILI using a fluence of 40 J/cm2 from lasers with wavelengths of 636, 825 and 1060 nm respectively. Post irradiation biochemical responses were analysed over a time period of 24, 48 and 72 h to obtain results on the cellular reaction as time elapse.

Cell culture

Commercially available lung cancer cells received from the ATCC were used in this study (A549, ATCC® CCL-185). The media used for culturing of lung cancer cells and isolated CSCs consisted of the following: Rosewell Park Memorial Institute 1640 medium (RPMI- 1640) (Sigma, R8758) supplemented with 10% foetal bovine serum (FBS) (Biochrom, S0615) and 0.5% penicillin/streptomycin (Sigma, P4333) and 0.5% amphotericin B (Sigma, A2942). Cultured cells were incubated at 37°C in 5% CO2 and 85% humidity.

Control cell line CaCO2 (ATCC®, HTB-37™) were cultured in Dulbecco’s Modified Eagle’s Media (DMEM) (Sigma, D5796) supplemented with 10% FBS (Biochrom, S0615), 2 mM L-Glutamine (Sigma, G7513), 1% penicillin/streptomycin (Sigma, P4333) and 1% amphotericin B (Sigma, A2942). SKUT-1 (ATCC®, HTB114™) was cultured in DMEM (Sigma, D5796) supplemented with 10% FBS (Biochrom, S0615) and 1% penicillin/streptomycin (Sigma, P4333) and 1% amphotericin B (Sigma, A2942).

Isolation of side population cells

The magnetic bead isolation kit and separation unit (Miltenyi Biotec, QuadroMACS™ separation unit 130-091-051) was used to isolate lung CSCs. The cells were magnetically labelled with microbead conjugated antibodies directed at the antigenic surface marker CD133. The cell population was enriched for CD133+ lung CSCs by using the CD133 MicroBead Kit (Miltenyi Biotec, CD133 MicroBead Kit, human 130-050-801) designed for the positive selection of cells expressing the human CD133 antigen.

The cell number was determined from a single cell suspension. The cells were spun down and re-suspended in 80 μl buffer and 20 μl Microbeads per 107 total cells, cells were then incubated for 15 minutes at 2-80°C. Cells were washed by using buffer solution from the kit through centrifugation at 3000 rpm for 10 min, then re-suspended in 500 μl buffer per 107 cells, which was repeated 3 times. Separation columns were prepared by running buffer through the column and discarding the effluent. The microbead conjugated cell suspension was carefully added to the prepared separation column (Miltenyi Biotec, 130-042- 201), avoiding cell clumps which would cause the cells to get stuck in the column. Cells which were unlabelled would flow through the column and were collected in a collection tube and discarded. Positively selected cells would remain in the magnetic column, which would then be flushed out into a suitable collection tube using buffer and a plunger.

Protein detection of CD133

To confirm whether cells isolated using the magnetic bead kit, were of CSC origin, cells were fluorescently labelled for the antigenic marker CD133. Anti-CD133 (Prominin-1), a rabbit monoclonal antibody (Abnova, PAB12663), was used. Isolated cells along with control cell lines CaCO2 and SKUT-1 were placed in a suspension where they were washed twice with ice-cold phosphate-buffered saline (PBS)/bovine serum albumin (BSA)/azide buffer (Sigma, P4417); 0.1% w/v BSA (Sigma, A2153); 0.01% w/v azide (Sigma, S8032) and then incubated with 10% serum (Normal Goat Serum, abcam, ab7481) for 30 min. on ice as a blocking step and washed twice as previously described. Cells were then incubated with 100 μl primary antibody, rabbit antihuman CD133+ (Abnova, PAB12663), in working buffer (2% serum in PBS BSA/azide buffer) for 30 min, keeping the cells suspended in tubes on ice. Cells were then rinsed three times with PBS BSA/azide buffer and incubated with 100 μl of the secondary fluorescent antibody, mouse anti-rabbit (abcam, ab6717) in working buffer for 30 min on ice, protected from light where after they were washed again with PBS BSA/Azide. The antigenic detection was done using a flow cytometer (FACSDiva Version 6.1.3 Flow Cytometer, BD Biosciences) which detects the fluorescence on the conjugated antibody, indicating if the cells are CD133 positive/negative.


Cells were irradiated from above, at room temperature with the culture dish lid off. Irradiation was performed in the dark omitting nuisance variables that would interfere with the laser effect such as polychromatic light. Cell cultures were divided into 5 study groups. Group 1 was an un-irradiated control, group 2 received irradiation at 5 J/cm2, group 3 was irradiated at 10 J/cm2, group 4 irradiated with a fluence of 20 J/cm2 and group 5 with 40 J/cm2, all with the respective wavelengths. Laser parameters are indicated in Table 1. Postirradiation, cells were incubated for 24, 48 or 72 h. Pre-irradiation cells were prepared in the following way: isolated lung CSCs were seeded at a concentration of 1 × 105 in 3.5 cm diameter treated plastic dishes.

Laser type Semiconductor (Diode)    
Wavelength (nm) 636 825 1060
Wave emission Continuous Continuous   Continuous
Power output (mW) ± 85 ± 85  ± 85
Power density (mW/cm2) 9.36 9.36 9.36
Spot size (cm2) 9.1 9.1 9.1
Fluence (J/cm2)
Duration of irradiation ± min sec
5, 10, 20 and 40
8 min 54 sec
17 min 48 sec
35 min 36 sec and
71 min 13 sec
5, 10, 20 and 40
8 min 54 sec
17 min 48 sec
35 min 36 sec and
71 min 13 sec
5, 10, 20 and 40
8 min 54 sec
17 min 48 sec
35 min 36 sec and
71 min 13 sec

Table 1: Laser parameters using the 636, 825 and 1060 nm diode lasers.

Each petri dish containing cells received 3 ml of complete media and incubated over night for attachment. After 24 h incubation at 370°C, the monolayer was rinsed 3 times with HBSS, where after another 3 ml of complete media was added before irradiation. In order to calculate the amount of energy the cells were going to receive, the power output of the laser was obtained using a power meter, the exposure time was calculated in order for the cells to receive energy with a fluence of 5-40 J/cm2. The culture dish containing the isolated cells were then placed directly into the irradiation beam. The beam of the laser was delivered through an optical fibre of 0.5 mm diameter, which allows for even distribution of monochromatic light on to the cultured cells. The tip of the fibre was positioned at a suitable distance from the culture dish. During cell irradiation, illumination of the entire culture dish was achieved as the beam diameter was set at 3.5 cm, allowing for all the cells to receive the same amount of energy from the laser.


The number of viable cells was determined using the dye exclusion test. With this assay live (viable) cells with intact membranes will exclude certain dyes such as trypan blue and remain colourless, whereas dead (non-viable) cells will retain the dye and stain blue. Ten microliters of cell suspension was added to 10 μl of 0.4% Trypan blue (Sigma Aldrich, T8154) and carefully mixed. A volume of 10 μl was transferred to a chamber slide which was then inserted into an automated cell counter (Countess® Automated Cell Counter) which visually depicts the cells and then electronically determined the percentage of viable cells.


ATP is the specialised carrier of energy within a cell. The quantification of ATP indicates the presence of metabolically active cells. The ATP luminescence assay was performed to assess cell proliferation using the CellTiter-Glo® luminescent cell proliferation assay (Promega, G7570). The ATP assay exploits the properties of luciferase to generate a sensitive stable luminescent signal and prevents endogenous ATP released during cell lysis.

Fifty microliters of ATP CellTiter-Glo® reagent was added to an equivalent volume of cell suspension in an opaque-walled 96 well plate (BD Biosciences, 353296). The plate was mixed on an orbital shaker at 250 rpm (Heidolph Polymax Orbital, Labotec, 1040) for 2 min to induce lysis and incubated for 10 min at room temperature in the dark. The application led to the production of a luminescent signal that was measured using a Multilabel Counter (Perkin Elmer, VICTOR3™, 1420) in RLU. For a background control, 50 μl of media was included into a well containing no cells. The RLU value obtained from the background control well was deducted from all the RLU values from the wells containing samples.


Cytotoxicity was assessed by measuring the amount of LDH released from the cytosol due to membrane damage. This oxidoreductase interconverts lactate into pyruvate. Its discharge from the cytosol leads to an unusual increase of the enzyme in the bloodstream in vivo or culture media in vitro. In the nonradioactive colorimetric assay, LDH reacted to convert a tetrazolium salt (in the reconstituted reagent, oxidised form) into a quantifiable red formazan product (reduced form) in a NADH dependent reaction. The product of this enzymatic reaction is proportional to the number of cells that have been lysed or damaged.

Cytotoxicity was evaluated using the CytoTox96® nonradioactive cytotoxicity assay (Promega, G400). Fifty microliters of reconstituted reagent was added to an equal volume of culture media in a 96 well plate and incubated in the dark at room temperature for 30 min. The colorimetric compound was measured spectrophotometrically at 490 nm using a multilabel Counter (Perkin Elmer, VICTOR3™, 1420).


Results were accumulated and processed using Sigma plot version 12. All assays were repeated at least four times. All error bars represent standard error of the mean (SEM) (n=4). For statistical evaluation, Student’s paired t-test was used, and significance was defined as p<0.05(*), p<0.01(**) or p<0.001(***). For fluorescence emission intensity analysis, a background subtraction was performed for all of the data.


Protein detection of CD133

Positive identification of CD133 isolated CSCs was performed using flow cytometric antibody identification. Secondary antibody immunofluorescent labelling technique was used to label the CD133 antigen on the isolated CSCs. Where the secondary antibody was FITC bound. Expression of the marker was seen on the isolated lung CSCs, as well as the positive control cell line CaCO2. No fluorescence was observed from the negative control cell line SKUT-1. Positive expression of the CD133 antigenic surface marker indicated positive isolation of lung CSCs. The majority of the cell population was identified as CSCs. Results indicated that the cells isolated had been characterised as CD133 positive shown in Figure 1 [33].


Figure 1: Identification of CD133 positive cells. Sample 1 and 2 are isolated lung CSCs and CaCO2 positive control which have been labelled with CD133 indicating positive gating for CD133 identification. Sample 3 which is SKUT-1 the negative control shows gating outside the population indicative of negative identification of the marker CD133 [33].


The percentage viability of cells post irradiation with LILI at 636 nm, 825 nm and 1060 nm with LF-LILI of 5, 10 and 20 J/cm2 and HFLILI of 40 J/cm2 is demonstrated in Tables 2-4.

  636 nm
    5 J/cm2 10 J/cm2 20 J/cm2 40 J/cm2
24 h Control 89.25 ± 1.65 86.25 ± 1.88 83 ± 2.12 84.25 ± 1.93
Test 87.5 ± 2.02 90.75 ± 2.28 83 ± 2.67 78.75 ± 2.09
48 h Control 87.75 ± 0.85 83.75 ± 2.86 86 ± 2.27 89 ± 1.41
Test 89.5 ± 1.32 88.75 ± 2.86 87.75 ± 2.28 83.5 *± 1.32
72 h Control 88.25 ± 1.37 87 ± 1.47 88.5 ± 1.55 89 ± 1.68
Test 88.5 ± 1.93 92 ± 1.47 89.25 ± 1.10 82 **± 1.47

Table 2: Percentage Trypan Blue viability of isolated CD133 lung CSCs measured at 636 nm.

825 nm
  5 J/cm2 10 J/cm2 20 J/cm2 40 J/cm2
24 h Control 86.25 ± 1.88 83.00  ± 2.12 89.00 ± 1.68 87.75  ± 0.85
Test 88.25 ± 1.88 93.00 *± 2.12 87.75 ± 2.13 77.75 *** ± 0.85
48 h Control 86.00 ± 2.27 89.00  ± 1.41 78.75 ± 2.09 88.25  ± 1.37
Test 88.00 ± 2.27 96.50 **± 1.25 83.25 ± 2.28 78.25 *** ± 1.18
72 h Control 84.25 ± 1.93 87.00  ± 1.47 82.00 ± 1.47 86.25  ± 1.88
Test 86.25 ± 1.93 96.75 ** ± 1.31 80.75 ± 2.05 74.00 **  ± 2.16

Table 3: Percentage Trypan Blue viability of isolated CD133 lung CSCs measured at 825 nm.

1060 nm
  5 J/cm2 10 J/cm2 20 J/cm2 40 J/cm2
24 h Control 89.00 ± 1.68 84.25 ± 1.93 83.00 ± 2.12 87.75 ± 0.85
Test 88.50 ± 0.64 87.75 ± 1.88 85.00 ± 1.58 84.75 *  ± 1 ± 0.85
48 h Control 82.00 ± 1.47 86.00 ± 2.27 78.25 ± 1.18 88.25 ± 1.37
Test 85.00 ± 0.85 89.00 ± 2.27 77.75 ± 1.49 84.25 ± 1.93
72 h Control 87.00 ± 1.47 86.25 ± 1.88 86.25 ± 1.88 82.00 ± 1.47
Test 89.00 ± 1.58 89.25 ± 1.88 84.50 ± 1.84 78.00 ± 1.22

Table 4: Percentage Trypan Blue viability of isolated CD133 lung CSCs measured at 1060 nm

The percentage of viable cells post irradiation did not show any significant increase in viability when using fluences of 5-20 J/cm2. Although a significant decrease in viability was seen when using HFLILI of 40 J/cm2 at 48 h and 72 h. This indicated membrane damage of those cells irradiated leading to a decrease in percentage viability (Table 2).

LILI using a wavelength of 825 nm had significant changes on percentage viability of isolated lung CSCs. Statistical significances were observed for 10 J/cm2 at 24 h (p<0.05), 48 h (p<0.01) and 72 h (p<0.01). Indicating that LILI have an increasing effect on viability leading to enhanced membrane integrity. A significant decrease was seen for 40 J/cm2 for the incubation periods of 24 h and 48 h (p<0.001). At 72 h a significant decrease in viability of p<0.01 was seen. HF-LILI had severely decreased viability, indicating diminished membrane integrity (Table 3).

Irradiation of isolated lung CSCs at 1060 nm did not produce any significant effect on viability of the cells. A significant decrease was observed when using HF-LILI of 40 J/cm2 at 24 h post irradiation. After 48 h and 72 h percentage viability was similar to their controls (Table 4).


Cell proliferation can be measured according to the ATP levels present over a period of time. As metabolically active cells produce greater amounts of ATP than cells which are starting to die. These levels can be measured at several time intervals to produce a growth trend of viable cells. ATP will induce proliferation in cells which is directly proportional to the cells metabolic rate controlled by the mitochondrion. Results are indicated as follows (Figures 2-4). All samples indicated an increase in proliferation as time elapse from 24 h to 72 h. This was due to metabolically active cells aiding in the proliferation rate.


Figure 2: ATP proliferation of isolated CD133 lung CSCs measured at 636 nm. All irradiated test samples were compared to their respective controls. Test samples received irradiation at fluence of 5-40 J/cm2. Statistical significances were observed at 10 J/cm2 having an increase in proliferation with a p-value of <0.05 (*). A significant decrease in proliferation was observed at 40 J/cm2 indicating p<0.05 (*). The changes observed at 5 J/cm2 and 20 J/cm2 weren’t significant (p<0.05(*), p<0.01(**) or p<0.001(***)).


Figure 3: ATP proliferation of isolated CD133 lung CSCs measured at 825 nm. All irradiated test samples were compared to their respective controls. Test samples received irradiation at a fluence of 5-40 J/cm2. Statistical significances were observed at 10 J/cm2 having an increase in proliferation with a p value of <0.01 (**). A significant decrease in proliferation was observed at 40 J/cm2 indicating p<0.01 (**). A significant difference was observed for 5 J/cm2, p<0.05 at 48 h. Other changes observed at 5 J/cm2 and 20 J/cm2 did not show any significance (p<0.05(*), p<0.01(**) or p<0.001(***)).


Figure 4: ATP proliferation of isolated CD133 lung CSCs measured at 1060 nm and 5, 10, 20 and 40 J/cm2. A significant decrease in proliferation was observed at 40 J/cm2 after 48 and 72 h indicating p<0.05(**). (p<0.05(*), p<0.01(**) or p<0.001(***)).

Irradiation at 636 nm produced a definitive rise in cellular proliferation, which increased after each incubation period of 24 h. Significant changes were seen at 10 J/cm2 where test samples compared to their controls had a significant stimulation in mitochondrial activity leading to increased levels of ATP (p<0.05). This change was observed for all three incubation periods. Although a significant decrease was observed for 40 J/cm2 (p<0.05), where irradiation induced a decrease in metabolic activity using a high fluence of LILI.

Results indicated that irradiating isolated lung CSCs at 825 nm had the most significant effects on the cellular metabolic rate, as most fluences presented with a significant change in ATP levels. An increase in proliferation was observed at 5 J/cm2 after three incubation periods of 24 hours each. A significance was seen at 48 h (p<0.05). Evaluation of test samples post irradiation of 10 J/cm2 showed significant changes with a p value of <0.01 for all incubation periods, having more significant effects than 636 nm and 1060 nm. Irradiation at 20 J/cm2 did not produce significant changes when comparing tests to their controls, although a similar trend in proliferation was observed over time. There was a definitive decrease in ATP levels observed post LILI of 40 J/cm2. Where after 24 h a significant decrease of p<0.05 was seen and at 48-72 h a decrease of p<0.01 were observed at both incubation periods. This significant decrease showed to be greater than that of 636 nm and 1060 nm.


The level of LDH released was assessed using the CytoTox96® nonradioactive cytotoxicity assay which measured the amount of LDH that was released into the culture media. This measurement describes the degree of cell damage related to membrane damage of the isolated lung CSCs. LDH that was released from the cytosol was quantified by absorbance measurement. Treated cells when compared to their controls released notable although statistically insignificant amounts of LDH in all wavelengths using fluences of 5-20 J/cm2 having similar absorbance values. An increase in cell damage was observed with treatment of 40 J/cm2 at wavelengths 636 nm, 825 nm and 1060 nm when compared to the controls and other fluences which was significant having a p value of <0.05 (Tables 5-7).

636 nm
  24 h 48 h 72 h
5 J/cm2 Control 0.3470 ± 0 0.3950 ± 0 0.3900 ± 0
Test 0.3440 ± 0 0.3883 ± 0 0.4008 ± 0.01
10 J/cm2 Control 0.3980 ± 0 0.4360 ± 0 0.4470 ± 0
Test 0.4263 ± 0.01 0.4540 ± 0.01 0.4513 ± 0.01
20 J/cm2 Control 0.5630 ± 0 0.6080 ± 0 0.6490 ± 0
Test 0.6183 ± 0.02 0.6123 ± 0 0.6535 ± 0.02
40 J/cm2 Control 0.6780 ± 0 0.7100 ± 0 0.6580 ± 0
Test 1.1998 *± 0.11 0.9570 *± 0.04 0.8673 *± 0.01

Table 5: LDH cytotoxicity of isolated CD133 lung CSCs measured at 636 nm. Test samples received irradiation of 5-40 J/cm2. There was only a significant amount of toxicity observed when comparing test samples to their controls at 40 J/cm2 (p<0.05*). Other comparisons did not yield any significant LDH cytotoxicity.

825 nm
  24 h 48 h 72 h
5 J/cm2 Control 0.3070 ± 0 0.3520 ± 0 0.4020 ± 0
Test 0.3563 ± 0.02 0.3675 ± 0.01 0.4363 ± 0.02
10 J/cm2 Control 0.4210 ± 0 0.4330 ± 0 0.4410 ± 0
Test 0.4265 ± 0.01 0.4258 ± 0.01 0.4398 ± 0
20 J/cm2 Control 0.5950 ± 0 0.6000 ± 0 0.6310 ± 0
Test 0.6293 ± 0.01 0.6413 ± 0.01 0.6473 ± 0.01
40 J/cm2 Control 0.6910 ± 0 0.6720 ± 0 0.7020 ± 0
Test 1.3306 *± 0.07 1.0738 *± 0.06 1.0405 *± 0.01

Table 6: LDH cytotoxicity of isolated CD133 lung CSCs measured at 825 nm. Test samples received irradiation of 5-40 J/cm2. When comparing test samples to their nonirradiated controls only 40 J/cm2 showed significant LDH release (p<0.05*). Other comparisons did not yield any significant LDH cytotoxicity.

1060 nm
  24 h 48 h 72 h
5 J/cm2 Control 0.3280 ± 0 0.3710 ± 0 0.3490 ± 0
Test 0.3348 ± 0 0.3855 ± 0 0.3963 ± 0.02
10 J/cm2 Control 0.4090 ± 0 0.4290 ± 0 0.4180 ± 0
Test 0.4083 ± 0 0.4385 ± 0.01 0.4430 ± 0.01
20 J/cm2 Control 0.4890 ±  0 0.5630 ± 0 0.5810 ± 0
Test 0.5310 ± 0.01 0.5840 ± 0.01 0.5935 ± 0
40 J/cm2 Control 0.6240 ± 0 0.6670 ± 0 0.6580 ± 0
Test 1.1878 *± 0.04 0.9360 *± 0.01 0.8330 *± 0.04

Table 7: LDH cytotoxicity of isolated CD133 lung CSCs measured at 1060 nm. Irradiation fluence ranged from 5-40 J/cm2. Controls received no irradiation. When comparing tests to their respective controls only 40 J/cm2 indicated a significant amount of cytotoxicity (p<0.05*). Changes seen in other fluences did not have a significant amount of LDH leakage.


In this study we explored the possible outcomes of LILI on lung CSCs. Promonin 1 (CD133) a pentaspan transmembrane glycoprotein, which is an antigenic structure usually found on stem cell surfaces [34] was used in this study for positive identification and isolation of CD133 lung CSCs. Positive isolation of CSCs was achieved using antigenic marker CD133, which was confirmed by previous studies stating that CSCs can be identified and isolated using their antigenic markers [35] and that CD133 have previously been used to identify and isolate different SCs and CSCs [36]. Antigenic identification of the surface marker CD133 was performed using control cell lines. The positive control cell line was CaCO2, which is a colorectal carcinoma cell line positive for the antigen CD133 [36] and negative control cell line SKUT-1 human uterus leiomyosarcoma, which do not express the surface marker. Results deduced from viability and proliferation assays show either a biostimulatory or bioinhibitory effect on the isolated CSCs depending on the wavelength and fluence used. The biostimulatory effect which had the greatest statistical significance was seen when using LF-LILI of 10 J/cm2 and a wavelength of 825 nm. Other stimulatory effects were seen when irradiating cells with a wavelength of 636-825 nm and fluence of 5-10 J/cm2 concurring with previous research who have found similar results [23,27,28]. CSC self-renewal capabilities help them oppose cell death and damage [6]. This phenomenon was seen during treatment of CSCs with an increased energy level of 20 J/cm2, as compared to non-cancerous cell lines which have died during exposure to increased energy levels [27]. These findings suggest a biostimulatory effect can be achieved on CSCs using irradiation between 5 and 20 J/cm2 with wavelengths ranging from 636 nm-1060 nm. Bioinhibition, having great statistical significance, was seen when irradiating samples with HF-LILI at 40 J/cm2 when analysing viability and proliferation results. The above findings show that parameters such as wavelength, fluence and intensity play an important role in photobiomodulation of cellular metabolism [24,26-28]. There was little to no significance seen on isolated CSCs when treated with a wavelength of 1060nm and fluence of 5-20 J/cm2 having no metabolic effect on the cells. These results reveal that CSC photobiostimulation is only achieved using visible red light with wavelengths ranging between 636 and 825 nm. Infra-red light (1060 nm) has little to no effect on CSC metabolism using LF-LILI. Cytotoxicity analysis revealed cells treated with LF-LILI (5-20 J/cm2) using all respective wavelengths did not show any membrane damage as no significant amounts of LDH were released. High levels of LDH were seen when treating samples with HF-LILI of 40 J/cm2 indicating significant membrane damage to the cells. Membrane damage can be directly related to cell death.

The hypothesis stating that CSCs contribute to cancer initiation, metastasis and relapse [37] raises concern not only when considering the development of cancer treatments but to the use of LILI as a photobiomodulative therapy. Modern day cancer therapies have restricted prognostic outcomes, lacking in its ability to kill CSCs along with the bulk of the tumour and produce adverse side effects. Research need to explore alternate therapies that include CSCs and their characteristics when developing treatments. When using LILI as a therapeutic model, one should take caution and consider the CSC characteristics, explicitly when applying LILI for its desired effects of increased cell proliferation and viability, [23] which poses to be harmful when considering treatment when CSCs are involved.

It shows to be apparent when developing cancer therapies that CSC death would be a promising approach and that focus need to be shifted towards achieving tumour cell specificity and exploiting cell death mechanisms whereby not only differentiated cancer cells but CSCs are also killed [38]. Obtaining statistical evidence pertaining the mechanism behind CSC cell death through induction of HF-LILI would be required for the clinical application of low-power laser therapies. Since lung cancer consists of a heterogenic cell population including lung CSCs, multiple signalling pathways have to be studied and targeted for effective therapeutic benefit [39].

It has been shown that LILI can deliver apoptotic stimulatory triggers in cancer and CSCs [33,38]. Previous studies conducted on A549 lung cancer using LILI indicated no significant changes in cellular viability, proliferation and cytotoxicity when using a wavelength of 636 nm. Indicating no significant effect without addition of a photosensitiser [40]. Photodynamic therapy, a cancer treatment that uses a photosensitive chemical which is activated by laser light, have been seen to induce membrane damage and apoptosis leading to cell death in lung cancer. The effectiveness of this treatment should be elaborated on by conducting experiments on lung CSCs, identifying its cell death mechanisms and whether there is a difference in cancer and CSC death.


This work was conducted at the Laser Research Centre at the University of Johannesburg and was supported by the National Laser Centre of South Africa.

Conflict of Interest

The authors indicate no potential conflict of interest.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • 4th World Congress on Human Genetics and Genetic Diseases April 19-20, 2018 Dubai, UAE
    April 19-20, 2018 Dubai, UAE
  • 3rd International Conference on Molecular Medicine and Diagnostics April 19-20, 2018 Dubai,UAE
    April 19-20, 2018 Dubai, UAE
  • 11th World Congress on Cell & Tissue Science May 09-10, 2018 Tokyo, Japan
    July 19-20, 2018 Dubai, UAE
  • 11th World Congress on Cell & Tissue Science May 09-10, 2018 Tokyo, Japan
    May 09-10, 2018 Tokyo, Japan
  • 6th International Conference on Integrative Biology May 21-23, 2018 Barcelona, Spain
    May 21-23, 2018 Barcelona, Spain
  • 10th International Conference on Genomics and Molecular Biology May 21-23, 2018 Barcelona, Spain
    May 21-23, 2018 Barcelona, Spain
  • 12th Annual Conference on Stem Cell and Regenerative Medicine June 04-06, 2018 Prague, Czech Republic
    June 04-06, 2018 Prague, Czech Republic
  • 4th International Conference on Bioscience July 2-3, 2018 Vienna, Austria
    July 2-3, 2018 Vienna, Austria
  • 22nd World Congress on Biotechnology July 10-11, 2018 Bangkok, Thailand
    April 16-18, 2018 Amsterdam, Netherlands
  • 9th International Conference on Tissue Science and Regenerative Medicine July 13-14, 2018 Sydney, Australia
    April 23-24, 2018 Las Vegas, USA
  • 10th Annual Conference on Stem Cell and Regenerative Medicine August 13-14, 2018 London, UK
    August 13-14, 2018 London, UK
  • World Congress on Stem Cell Biology and Biobanking September 3-4, 2018 Tokyo, Japan
    September 3-4, 2018 Tokyo, Japan
  • 2nd Annual summit on Cell Metabolism and Cytopathology September 19 - 20, 2018 Philadelphia, Pennsylvania, USA
    September 19 - 20, 2018 Philadelphia, USA
  • 2nd Annual summit on Cell Signaling and Cancer Therapy September 19 - 20, 2018 Philadelphia, Pennsylvania, USA
    September 19 - 20, 2018 Philadelphia, USA
  • 6th Annual Congress on Biology and Medicine of Molecules September 20-21,2018 Kuala Lumpur, Malaysia
    September 20-21,2018 Kualalumpur, Malaysia
  • 5th International Conference on Human Genetics and Genetic Disorders September 21-22,2018 Philadelphia, Pennsylvania, USA
    September 21-22,2018 Philadelphia, USA
  • 11th International Conference on Genomics and Pharmacogenomics September 21-22, 2018 Philadelphia, Pennsylvania, USA
    September 21-22, 2018 Philadelphia, USA
  • 5th World Congress on HUMAN GENETICS SEPTEMBER 24-25, 2018 BERLIN, GERMANY
    SEPTEMBER 24-25, 2018 Berlin, Germany
  • 21st Euro Biotechnology Congress October 11-12, 2018 Moscow, Russia
    October 11-12, 2018 Moscow, Russia
  • 11th International Conference on Tissue Engineering & Regenerative Medicine October 18-20, 2018 Rome, Italy
    October 18-20, 2018 Rome, Italy
  • 24th Biotechnology Congress: Research & Innovations October 24-25, 2018 Boston, USA
    October 24-25, 2018 Boston, USA
  • International Conference on Human Genome Meeting October 25-26, 2018 Istanbul, Turkey
    October 25-26, 2018 Istanbul, Turkey
  • International Congress & Expo on Genomics and Bioinformatics November 2-3, 2018 Columbus, Ohio, USA
    November 2-3, 2018 Columbus, USA
  • 12th International Conference & Exhibition on Tissue Preservation and Biobanking November 9-10, 2018 Atlanta, Georgia, USA
    November 9-10, 2018 Atlanta, USA
  • 2nd Annual Summit on Cell Therapy and Stem Cell Research November 9-10, 2018 Atlanta, Georgia, USA
    November 9-10, 2018 Atlanta, USA

Article Usage

  • Total views: 942
  • [From(publication date):
    December-2016 - Mar 24, 2018]
  • Breakdown by view type
  • HTML page views : 860
  • PDF downloads : 82

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version